Affinity of angiotensin i-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ace is different in heart, lung, arteries, and veins

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 4, 1996, Pages 494-499

  Bevilacqua, Maurizio ^a,b   Vago, Tarcisio ^a   Rogolino, Angela ^a   Conci, Fabrizio ^a   Santoli, Edoardo ^a   Norbiato, Guido ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiotensin converting enzyme; C Site; Captopril; Delapril; N Site

Indexed keywords

9 [1 CARBOXY 3 (4 HYDROXYPHENYL)PROPYLAMINO] 10 OXOPERHYDROPYRIDAZINO[1,2 A][1,2]DIAZEPINE 1 CARBOXYLIC ACID; 9 [1 CARBOXY 3 (4 HYDROXYPHENYL)PROPYLAMINO] 10 |OXOPERHYDROPYRIDAZINO[1,2 A][1,2]DIAZEPINE 1 CARBOXYLIC ACID; CAPTOPRIL; DELAPRILAT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; UNCLASSIFIED DRUG;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORONARY ARTERY; ENZYME GLYCOSYLATION; FEMALE; HEART; HUMAN; HUMAN TISSUE; LUNG; MALE; MAMMARY ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SAPHENOUS VEIN; TESTIS;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIES; BINDING SITES; CAPTOPRIL; CELL MEMBRANE; CORONARY VESSELS; ENALAPRILAT; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG; MALE; MAMMARY ARTERIES; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; PYRIDAZINES; RADIOLIGAND ASSAY; RATS; SAPHENOUS VEIN; TESTIS; VEINS;

EID: 0029740140     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199610000-00003     Document Type: Article

References (54)

1. Erdors EG. Angiotensin I converting enzyme and the changes of our concepts through the years. Hypertension 1990;16:363-70.
2. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry 1989;28:5311-7.
3. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: zinc and inhibitor-binding stochiometrics of somatic and testis isozymes. Biochemistry 1991;30:7118-26.
4. Soubrier F, Alhenc-Gelas, Hubert C. et al. Two putative active centres in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Notl Acad Sci USA 1988;85:9386-90.
5. Bernestein KE, Martin BM, Edwards SAS, Bernestein EA. Mouse angiotensin-converting enzyme is a protein composed of two homologous domains. J Biol Chem 1989;264:11945-51.
6. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993;268:9496-503.
7. Perich RB, Jackson B, Attwood MR, Prior K, Johnston CI. Angiotensin converting enzyme inhibitors act at two different binding sites on angiotensin converting enzyme. Pharm Pharmacol Lett 1991;1:41-3.
8. Perich RB, Jackson B, Rogerson F, Mendelsohn FAO, Paxton D, Johnston CI. Two binding sites on angiotensin-converting enzyme: evidence from radiological binding studies. Mol Pharmacol 1992;42:286-93.
9. Wei L, Alhenc Galas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I converting enzyme are both catalytically active. J Biol Chem 1991;266:9002-8.
10. Williams TA, Corvol P, Soubrier P. Identification of two active site residues in human angiotensin I-converting enzyme. J Biol Chem 1994;269:29430-4.
11. Ehlers MR, Fox EA, Strydom DJ, Riordan JF. Molecular angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993;268:9496-503.
12. Skidgel RA, Erdos EG. Novel activity of human angiotensin I-converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-release hormone. Proc Natl Acad Sci USA 1985;82:1025-9.
13. Danilov S, Jaspard E, Churakova T, et al. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. Selective inhibition of the amino-terminal active site. J Biol Chem 1994;269:2680.
14. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin I-converting enzyme. J Biol Chem 1995;270:3656-61.
15. Azizi M, Rousseau A, Ezan E, et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. J Clin Invest 1996;97:839-44.
16. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic of polymorphism of expression in T-lymphocytes. Biochem J 1993;290:33-40.
17. Aschoff JM, Lazarus D, Fanburg BL, Lanzillo JJ. Relative quantification of angiotensin-converting enzyme mRNA in human smooth muscle cells, monocytes. and lymphocytes by the polymerase chain reaction. Anal Biochem 1994;219:218-23.
18. Kozlowski S, Corr M, Takeshita T, et al. Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med 1992;175:1417-22.
19. Kozlowski S, Corr M, Shirai M, et al. Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides. J Immunol 1993;151:4033-44.
20. Ward WF, Molteni A, Ts'ao CH, Hinz JM. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys 1990;19:1405-9.
21. Nguyen L, Ward WF, Ts'ao CH, Molteni A. Captopril inhibits proliferation of human lung fibroblasts in culture: a potential antifibrotic mechanism. Proc Soc Exp Biol Med 1994;205:80-4.
22. Yoon SC, Park JMJ, Jang HS, Shinn KS, Bahk YW. Radioprotective effect of captopril on the mouse jejunal mucosa. Int J Radiat Oncol Biol Phys 1994;30:873-8.
23. Deddish PA, Wang J, Michel B, et al. Naturally occurring active N-domain of human angiotensin I-converting enzyme. Proc Natl Acad Sci VSA 1994;91:7807-11.
24. Kamchandran R, Sen GC, Misono K, Sen T. Regulated cleavagesecretion of the membrane-bound angiotensin-converting enzyme. J Biol Chem 1994;269:2125-30.
25. Wei L, Alhenc Gelas F, Soubrier F, Michaud A, Corvol P, Clauser F. Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem 1991;266:5540-6.
26. Kumar RS, Thehhumkara TJ, Sen GC. The mRNAs encoding the two angiotensin-converting isozymes are transcribed from the same gene by a tissue-specific choice of alternative transcription initiation sites. J Biol Chem 1991;266:3854-62.
27. Kumar RS, Kusarl J, Roy S, Soffer RL, Sen GC. Structure of testicular angiotensin-converting enzyme. A segmental isozyme. J Biol Chem 1989;264:16754-8.
28. Brée F, Hamon G, Tillement JP. Evidence for two binding sites on membrane-bound angiotensin converting enzymes (ACE) for exogenous inhibitors except in testis. Life Sci 1992;51:787-94.
29. Sibony M, Segretain D, Gase JM. Angiotensin-converting enzyme in murine testis: step-specific expression of the germinal isoform during spermiogenesis. Biol Reprod 1994;50:1015-26.
30. Perich RB, Jackson B, Johnston CI. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur J Pharmacol 1994;266:201-11.
31. Perich RB, Jackson B, Danilov SM, Johnston CI. Interaction of sulphydryl, phosphinyl and carboxyl inhibitors of angiotensin converting enzyme with the enzyme. [Abstract]. Fourth International-Second Asian-Pacific Symposium on ACE Inhibition, Beijing, April 24-28, 1995.
32. Vago T, Bevilacqua M, Conci C, et al. Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues. Br J Pharmacol 1992;107:821-5.
33. Bevilacqua M, Vago T, Monopoli A, et al. Alpha 1 adrenoceptor subtype mediates noradrenaline induced contraction of the human internal mammary artery: radioligand and functional studies. Cardiovasc Res 1991;25:290-4.
34. Hunter WM, Greenwood FC, Preparation of iodine 131 labeled human growth hormone of high specific activity. Nature 1962;194:495-6.
35. Vago T, Bevilacqua M, Conci F, Rogolino A, Norbiato G. Pharmacologic data reveal the heterogeneity of angiotensin-converting enzyme according to its source (lung versus heart). Am J Cardiol 1995;75:13F-7F.
36. Bradford N. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1975;72:248-52.
37. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for the characterization of ligand binding systems. Anal Biochem 1980;107:220-39.
38. Hill AV. The possible effect of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol (Lond) 1910;40:iv-vii.
39. Jackson B, Cubela R, Johnston CI. Characterization of angiotensin converting enzyme from rat tissue by radioinhibitor binding studies. Clin Exp Pharmacol Physiol 1986;13:681-9.
40. Jackson B, Cubela R, Johnston CI. Angiotensin converting enzyme (ACE), characterization by 125I-MK351A binding studies of plasma and tissue ACE during variation of salt status in the rat. J Hypertens 1986;4:759-65.
41. Oka Y, Nishikawa K, Kilo G. et al. Delapril. Cardiovasc Drug Rev 1988;6:192-205.
42. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993;43:1-20.
43. Dzau VJ. Local expression and pathophysiological role of reninangiotension in the blood vessels and heart. Basic Res Cardiol 1993;88(suppl):1-14.
44. Johnston C, Fabris B, Yoshida K. The cardiac renin-angiotensin system in heart failure. Am Heart J 1993;126:756-60.
45. Naftilan AJ. Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Curr Opin Nephrol Hypertens 1994;3:218-27.
46. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994;90:449-55.
47. Naim HY. Human small intestinal angiotensin-converting enzyme: intracellular transport, secretion and glycosylation. Biochem J 1993;296:607-15.
48. Ripka JE, Ryan JW, Valido FA, Chung AY, Peterson CM, Urry RL. N-Glycosylation of forms of angiotensin convening enzyme from four mammalian species. Biochem Biophys Res Commun 1993;196:503-8.
49. Kasturi S, Jabbar MA, Sen GC, Sen I. Role of glycosylation in the biosynthesis and activity of rabbit testicular angiotensin-converting enzyme. Biochemistry 1994;33:6228-34.
50. Benetau-Burmat B, Tahraoui A, Barbut F, Gibodeau J, Baudin B. Physiochemical and immunological comparisons between angiotensin I-converting enzymes purified from different mammalian species. Comp Biochem Physiol Biochem Mol Biol 1994;109:623-35.
51. Topouzis S, Catravas JD, Ryan JW, Rosenquist TH. Influence of vascular smooth muscle heterogeneity of angiotensin converting enzyme activity in chicken embryonic aorta and in endothelial cells in culture. Circ Res 1992;71:923-31.
52. Kirby ML, Waldo KL. Role of neural crest in congenital heart disease. Circulation 1990;82:332-40.
53. Poelmann RE, Gittenberger-de-Groot AC, Mentink MM, Bokenkamp R, Hogers B. Development of the cardiac coronary vascular endothelium: studies with antiendothelial antibodies, in chicken quail chimeras. Circ Res 1993;73:559-68.
54. Yosipiv IV, Dipp S, El-Dahr SS. Ontogeny of somatic angiotensinconverting enzyme. Hypertension 1994;23:369-74.